Real-world experience in the management of CML patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life.

IF 1.7 4区医学 Q3 HEMATOLOGY

Acta Haematologica Pub Date : 2025-01-10 DOI:10.1159/000542562

Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Young Eun Jang, Yunji Lee, Joon Ho Moon, Sang Kyun Sohn

{"title":"Real-world experience in the management of CML patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life.","authors":"Hee Jeong Cho, Dong Won Baek, Juhyung Kim, Young Eun Jang, Yunji Lee, Joon Ho Moon, Sang Kyun Sohn","doi":"10.1159/000542562","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML).Methods: Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed.Results: No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.301) or the sequence of TKIs used (p = 0.770). Among 182 patients treated with nilotinib, 25 experienced cardiovascular events (CVEs). After 10 years of nilotinib treatment, CVEs occurred in 55.2% of patients with ≥ 2 vascular risk factors. Pleural effusion was observed in 27 of 78 dasatinib-treated patients. In terms of HRQoL, patients treated with nilotinib generally reported higher satisfaction levels than did those treated with imatinib or dasatinib. When stratified by age or duration of TKI treatment, patients aged < 60 years or those with a treatment duration of ≥ 1 year exhibited better satisfaction levels.Conclusion: Survival outcomes were not affected by history of TKI treatment. Nilotinib is favorable for HRQoL but increases the risk of serious CVEs in patients with vascular risk factors.","PeriodicalId":6981,"journal":{"name":"Acta Haematologica","volume":" ","pages":"1-25"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Haematologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML).

Methods: Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed.

Results: No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.301) or the sequence of TKIs used (p = 0.770). Among 182 patients treated with nilotinib, 25 experienced cardiovascular events (CVEs). After 10 years of nilotinib treatment, CVEs occurred in 55.2% of patients with ≥ 2 vascular risk factors. Pleural effusion was observed in 27 of 78 dasatinib-treated patients. In terms of HRQoL, patients treated with nilotinib generally reported higher satisfaction levels than did those treated with imatinib or dasatinib. When stratified by age or duration of TKI treatment, patients aged < 60 years or those with a treatment duration of ≥ 1 year exhibited better satisfaction levels.

Conclusion: Survival outcomes were not affected by history of TKI treatment. Nilotinib is favorable for HRQoL but increases the risk of serious CVEs in patients with vascular risk factors.

查看原文本刊更多论文

在CML患者管理的实际经验集中在酪氨酸激酶抑制剂不耐受和健康相关的生活质量。

本研究旨在分析与长期使用酪氨酸激酶抑制剂（TKIs）相关的生存结局和不良事件（ae），并评估慢性髓性白血病（CML）患者的健康相关生活质量（HRQoL）。方法：回顾性分析345例经至少一种TKI治疗的CML患者的病历。结果：患者接受不同tki的次数（p = 0.301）和使用tki的顺序（p = 0.770）对生存率无显著差异。在182例接受尼罗替尼治疗的患者中，25例发生心血管事件（cve）。尼罗替尼治疗10年后，55.2%伴有≥2种血管危险因素的患者发生cve。78例达沙替尼治疗的患者中有27例出现胸腔积液。在HRQoL方面，接受尼罗替尼治疗的患者通常比接受伊马替尼或达沙替尼治疗的患者报告更高的满意度。当按年龄或TKI治疗时间分层时，年龄< 60岁或治疗时间≥1年的患者表现出更好的满意度。结论：生存结局不受TKI治疗史的影响。尼洛替尼有利于HRQoL，但会增加有血管危险因素患者发生严重cve的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Haematologica 医学-血液学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Acta Haematologica'' is a well-established and internationally recognized clinically-oriented journal featuring balanced, wide-ranging coverage of current hematology research. A wealth of information on such problems as anemia, leukemia, lymphoma, multiple myeloma, hereditary disorders, blood coagulation, growth factors, hematopoiesis and differentiation is contained in first-rate basic and clinical papers some of which are accompanied by editorial comments by eminent experts. These are supplemented by short state-of-the-art communications, reviews and correspondence as well as occasional special issues devoted to ‘hot topics’ in hematology. These will keep the practicing hematologist well informed of the new developments in the field.